Search the Community
Showing results for tags 'xtandi'.
Jim Marshall (not a doctor) said ... If you have castrate-resistant prostate cancer, common treatments that your doctor may add to your regular ADT treatment include: Docetaxel (Taxotere) Enzalutamide (Xtandi) or Abiraterone (Zytiga) Cabazitaxel (Jevtana). But what are your doctor's drug choices when the cancer is no longer under control after all three options? If you responded to docetaxel, your doctor knows you may well respond again to another dosing of docetaxel. But this increases your risk of side effects - especially peripheral neuropathy or nail di
Admin posted a topic in New agentsJim Marshall (not a doctor) said … One of the most important meetings of doctors for men with advanced prostate cancer is the ASCO (American Society of Clinical Oncology) meeting held each year. Yesterday at the ASCO meeting Dr Maha Hussain, on behalf of her team presented the initial results of the PROSPER clinical trial. That trial tested whether men with no metastases, but who had rapidly rising PSA, would do better with early Enzalutamide (Xtandi). This presentation is just the start of scientific reporting. Dr Hussain is presenting this study to hundreds of
Admin posted a topic in Any suggestions?Chalkie asks: I am now having to choose between Zytiga and Xtandi. Is there a forum for this? Any suggestions? Jim Marshall (not a doctor) said ... A recent trial for men with metastatic prostate cancer who were no longer responding to ADT alone (mCRPC) showed similar outcomes on both drugs. So, it appears your doctor could recommend either, unless they are worried about how a particular side effect may affect you personally: If you have a health condition that could be made worse by possible seizure or fatigue, your doctor may steer away from Xtandi.
Last Friday 10 March 2017 the Pharmaceutical Benefits Advisory Committee (PBAC) reached its initial decisions on drugs to go onto the PBS at reduced prices. This included whether to put Xtandi (Enzalutamide) before chemo on the PBS. The company will be told of the result next Friday 17 March 2017. If necessary, negotiations between the PBAC and the company continue for 4 weeks. The final results will be published on the PBAC website 21 April 2017. (If the company is not happy with the result, they have until July 2017 to appeal.)